10-Q: Calidi Biotherapeutics Q1 2026 Financial Update

Calidi Biotherapeutics reports a net loss of $4.1 million for Q1 2026, with a focus on advancing its RedTail platform and securing future funding.

Summary

• Calidi Biotherapeutics reported a net loss of $4.1 million for the first quarter ended March 31, 2026, compared to a net loss of $5.1 million in the same period of 2025.
• Total operating expenses decreased by 17% to $4.2 million from $5.1 million in the prior year's quarter, driven by a reduction in general and administrative expenses.
• Research and development expenses increased slightly by 7% to $2.6 million, attributed to higher drug manufacturing and preclinical costs.
• The company had $6.6 million in cash and $0.2 million in restricted cash as of March 31, 2026.
• Calidi Biotherapeutics has concluded that there is substantial doubt about its ability to continue as a going concern within 12 months.
• The company plans to raise additional capital through public or private equity or debt financings to fund operations for the next 12 months.
• Significant financing activities occurred, including a $5.1 million net proceeds from a March 2026 public offering.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant net loss, accumulated deficit, and the explicit statement of substantial doubt about the company's ability to continue as a going concern, despite some operational cost reductions.

Positives

• Reduction in total operating expenses by 17% to $4.2 million for Q1 2026 compared to Q1 2025.
• Decrease in general and administrative expenses by 39% to $1.6 million.
• Increase in cash balance to $6.6 million as of March 31, 2026.
• Successful completion of a $5.1 million public offering in March 2026.

Negatives

• Net loss of $4.1 million for Q1 2026.
• Accumulated deficit of $145.7 million as of March 31, 2026.
• Substantial doubt about the company's ability to continue as a going concern within 12 months.
• Continued expectation of operating losses and negative cash flows.
• Potential for dilution to existing shareholders due to future equity issuances.

Risks

• The company has experienced recurring losses and negative cash flows and expects them to continue, raising substantial doubt about its ability to continue as a going concern.
• The company's ability to continue as a going concern is dependent on its ability to raise additional funding, which may not be secured on favorable terms or at all.
• Issuing equity securities to raise funds may result in dilution for existing stockholders.
• Product candidates are subject to long development cycles, and the company may be unsuccessful in developing, obtaining regulatory approval for, or marketing them.
• Changes in economic conditions, public health issues, volatile equity markets, supply chain disruptions, and geopolitical conflicts may affect operations.
• The company is subject to litigation, including claims of defamation, constructive discharge, breach of fiduciary duty, and securities fraud.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through development, seeks regulatory approval, and operates as a public company. Future capital requirements are substantial, and the company plans to raise additional capital through equity or debt financings. The company anticipates filing an IND application for CLD-401 by the end of 2026.

Management Comments

• The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites.
• We believe that RedTail, given its systemic administration and targeting to metastatic sites and its delivery of genetic medicines, represents a major advancement in the space of oncolytic virus in oncology.
• Based on our operating plan, we believe we do not have sufficient cash on hand to support current operations for at least one year from the date of issuance of our unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2026. We have concluded that this circumstance raises substantial doubt about our ability to continue as a going concern.
• In connection with Mr. Camaisas decision, effective on the date of our 2026 annual stockholder meeting, the Board reduced the size of the Board from six (6) to five (5) directors.

Industry Context

StockSavvy.ai notes that Calidi Biotherapeutics is operating in the highly competitive and capital-intensive biotechnology sector, focusing on oncolytic virus therapies. The company's RedTail platform aims to address a key challenge in the field: systemic delivery to metastatic sites, differentiating it from earlier technologies like T-VEC. The ongoing need for significant capital to fund clinical development and regulatory processes is a common theme for companies at this stage.

Comparison to Industry Standards

• The company's net loss of $4.1 million for the quarter is in line with many early-stage biotechnology firms that are pre-revenue and heavily investing in R&D.
• The cash burn rate of approximately $4.1 million for operating activities in the quarter is typical for companies advancing drug candidates through preclinical and early-stage clinical trials.
• The substantial accumulated deficit of $145.7 million is also characteristic of biotechnology companies that have undergone significant R&D investment without substantial revenue generation.
• The company's reliance on public and private financings for liquidity is a standard practice in the biotech industry, though the success and terms of these financings can vary significantly.

Management Changes

Legal Proceedings

• Tony Kalajian filed a complaint alleging defamation and constructive discharge.
• Company initiated arbitration against Mr. Kalajian for breach of fiduciary duty, constructive fraud, conversion, and declaratory relief related to unauthorized bonuses.
• Hazel Sanchez filed a complaint alleging defamation, constructive discharge, violation of California Family Rights Act, and wrongful discharge.
• Company filed a Cross-Complaint against Ms. Sanchez for breach of fiduciary duty, constructive fraud, conversion, and declaratory relief related to unauthorized bonuses.
• Mr. Kalajian filed a complaint alleging intentional conversion and violation of Delaware General Corporations Code due to failure to remove a restrictive legend from shares.
• Company filed a lawsuit against a former executive assistant alleging breach of fiduciary duty, constructive fraud, conversion, and misappropriation of confidential information.
• Mr. Yian Zeng filed a complaint alleging securities fraud, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive fraud.

Related Party Transactions

• Severance accrual for Director F (Mr. Camaisa) totaling $63,000 as of March 31, 2026.
• Director F provided a personal Guaranty of Lease for the San Diego Lease, with accrued consideration of $20,000 as of March 31, 2026.
• Warrant liability involving Director F and Director A totaling $5,000 as of March 31, 2026.
• Severance accrual for Officer G totaling $4,000 as of March 31, 2026.
• Severance accrual for Officer A totaling $0.1 million as of March 31, 2026.
• Accounts payable and accrued expenses to Company A (related to Director G) totaling $51,000 as of March 31, 2026.
• The company has outstanding debt obligations, including promissory notes, which may involve related parties.

Stakeholder Impact

• Shareholders may experience dilution due to future equity issuances required for funding.
• The company's ability to continue as a going concern poses a risk to all stakeholders.
• Employees may be impacted by potential future cost-saving measures if funding is not secured.
• Creditors and suppliers may face payment uncertainties if the company cannot secure additional financing.

Next Steps

• Advance the RedTail platform and CLD-401 through preclinical and clinical development.
• File an investigational new drug (IND) application for a Phase I trial for CLD-401 by the end of 2026.
• Secure additional capital through public or private equity or debt financings.
• Continue operations as a public company, managing associated expenses.
• The Board size will be reduced from six to five directors following the 2026 annual stockholder meeting.

Key Dates

Recommendation

The company is in a critical stage of development with promising technology but faces significant financial challenges, including substantial doubt about its going concern status. While operational expenses have been reduced, the path to revenue is long and uncertain. Investors should hold positions for potential upside if financing is secured and development progresses, but the risks are considerable, warranting caution.

Keywords

Calidi Biotherapeutics, 10-Q, Quarterly Report, Biotechnology, Oncolytic Virus, RedTail Platform, CLD-401, Financial Results, Net Loss, Going Concern, Capital Raise, SEC Filing